Merck KGaA (OTCMKTS:MKGAF) Shares Up 5.1% - Still a Buy?

Key Points

• Shares jumped 5.1% mid-day to about $129.17 (high $129.30) on very light trading — just 110 shares exchanged, down ~81% from the average session volume of 594.
• The stock is still trading below its recent trend lines, with the 50-day and 200-day moving averages around $140, while the company has a market capitalization of $16.69 billion and a price-to-earnings ratio of 19.72.
• Merck KGaA is a long-established German chemical and pharmaceutical group (founded 1668) headquartered in Darmstadt and privately controlled by the Merck family, operating across three main business units globally.

Merck KGaA (OTCMKTS:MKGAF - Get Free Report)'s stock price shot up 5.1% during mid-day trading on Tuesday . The company traded as high as $129.3010 and last traded at $129.1690. 110 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 594 shares. The stock had previously closed at $122.9340.

Merck KGaA Stock Up 5.1%

The business's 50 day moving average is $140.06 and its 200-day moving average is $139.55. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.84 and a current ratio of 1.31. The firm has a market capitalization of $16.69 billion, a price-to-earnings ratio of 19.72 and a beta of 0.96.

About Merck KGaA

Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.

The company's operations are organized mainly into three businesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.